EFFICACY OF FIX DOSE COMBINATION (ATORVASTATIN AND AMLODIPINE) IN TREATMENT OF UNCONTROLLED HYPERTENSION AND DYSLIPIDEMIA
Abstract
Background: The fixed-dose combination containing the antihypertensive agent amlodipine and thestatin, atorvastatin, is the first combination of its kind designed to treat two risk factors forcardiovascular disease (CVD), i.e., hypertension and dyslipidemia. In this study, blood pressure andlipid lowering effects of combination of amlodipine and atorvastatin were evaluated in uncontrolledhypertensive patients. Methods: Thirty patients both male and female in the age group 35–60 yearsattending the Hypertensive Clinic of PMRC FJMC suffering from uncontrolled hypertension wereselected. Baseline blood pressure was checked after half hour rest in sitting and standing position usingmercury sphygmomanometer. Blood sample was collected from all patients after overnight fasting forassessment of serum cholesterol, triglycerides, LDL and HDL cholesterol levels. They were prescribedwith fixed dose combination of 5 mg amlodipine and 10 mg atorvastatin. Patients were followed fortheir blood pressure measurement after every 4 weeks up to 12 weeks. At the end of 12 weeks theirfasting blood sample was taken again for determination of serum cholesterol, triglyceride, LDL andHDL cholesterol levels. Results: Systolic blood pressure after 4, 8 and 12 weeks was significantlylower at all intervals from baseline. When systolic blood pressure after 8 and 12 weeks was comparedwith 4 weeks, the effect was again significant (p=0.024, p=0.002 respectively).There was no significantreduction seen in 8 versus 12 weeks (p=0.493). Diastolic blood pressure at 4, 8 and 12 weeks wassignificantly lower from baseline. Diastolic blood pressure after 4 and 8 weeks when compared with 8and 12 weeks was not significantly low (p=0.99 and 0.91 respectively). Lipid profile of the patients wassignificantly reduced from baseline after twelve weeks of fixed dose combination of treatment(p<0.000). Conclusion: Combination therapy proved to be effective in controlling hypertension anddyslipidemia than single pill. It also improved patient’s compliance. It is suggested that polypill shouldbe prescribed instead of multiple drugs.Keywords: combination therapy, atorvastatin, amlodipine, uncontrolled hypertension, dyslipidemiaReferences
Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, et
al. Heart disease and stroke statistics —2008 update: a report from
the American Heart Association Statistics Committee and Stroke
Statistics Subcommittee. Circulation 2008;117(4):e25–e146.
Volpe M, Alderman MH, Furberg CD, Jackson R, Kostis JB,
Laragh JH, et al. Beyond hypertension toward guidelines for
cardiovascular risk reduction Am J Hypertens 2004;17(11 Pt-
:1068–74.
National Center for Health Statistics Report. Feb 24, 2008.
Accessed on Jan 10, 2009. Available from: http://www.cdc.gov/
nchs
Iqbal SP, Dodani S, Qureshi R. Risk factors and behaviors for
coronary artery disease (CAD) among ambulatory Pakistanis. J
Pak Med Assoc 2004;54:261–6.
Heart Protection Study Collaborative Group. MRC/BHF Heart
Protection Study of cholesterol lowering with simvastatin in
,536 high-risk individuals: a randomised placebo-controlled
trial. Lancet 2002;360(9326):7–22.
Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield
M, et al. Prevention of coronary and stroke events with
atorvastatin in hypertensive patients who have average or lowerthan-average cholesterol concentrations, in the AngloScandinavian Cardiac Outcomes Trial–Lipid Lowering Arm
(ASCOT-LLA): a multicentre randomised controlled trial. Lancet
;361(9364):1149–58.
Turnbull F. Effects of different blood-pressure-lowering
regimens on major cardiovascular events: results of
prospectively-designed overviews of randomised trials. Lancet
;362(9395):1527–35.
Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil
HA, Livingstone SJ, et al. Primary prevention of cardiovascular
disease with atorvastatin in type 2 diabetes in the Collaborative
Atorvastatin Diabetes Study (CARDS): multicentre randomised
placebo-controlled trial. Lancet 2004;364(9435):685–96.
Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S,
Hansson L et al. Outcomes in hypertensive patients at high
cardiovascular risk treated with regimens based on valsartan or
amlodipine: the VALUE randomised trial. Lancet
;363(9426):2022–31.
Blank R, LaSalle J, Reeves R, Maroni J, Tarasenko L, Sun F.
Single-pill therapy in the treatment of concomitant hypertension
and dyslipidemia (the amlodipine/atorvastatin gemini study). J
Clin Hypertens (Greenwich) 2005;7(5):264–73.
Chung M, Calcagni A, Glue P, Bramson C. Effect of food on the
bioavailability of amlodipine besylate/atorvastatin calcium
combination tablet. J Clin Pharmacol 2006;46(10):1212–6.
Preston RA, Harvey P, Herfert O, Dykstra G, Sun F, Maroni J, et
al. Reduction in Framingham cardiovascular risk with
concomitant treatment of hypertension/dyslipidemia with
amlodipine/atorvastatin. Am J Hypertens 2005;18:A226.
Messerli FH, Bakris GL, Ferrera D, Houston MC, Petrella RJ,
Flack JM, et al. Efficacy and safety of co-administered
amlodipine and atorvastatin in patients with hypertension and
dyslipidemia: results of the AVALON trial. J Clin Hypertens
(Greenwich) 2006;88:571–81; quiz 582–3.
Preston RA, Sun F, Tarasenko L. Safety and tolerability of coadministered amlodipine and atorvastatin in patients with
concomitant hypertension and dyslipidemia in the Respond
study. Am J Hypertens 2005;18:A92–3.
Devabhaktuni M, Bangalore S. Fixed combination of amlodipine
and atorvastatin in cardiovascular risk management: patient
perspectives. Vasc Health Risk Manag 2009;5:377–87.
Preston RA, Harvey P, Herfert O, Dykstra G, Jukema JW, Sun F,
et al. A randomized, placebo-controlled trial to evaluate the
J Ayub Med Coll Abbottabad 2011;23(3)
http://www.ayubmed.edu.pk/JAMC/23-3/Saira.pdf
efficacy, safety, and pharmacodynamic interaction of
coadministered amlodipine and atorvastatin in 1660 patients with
concomitant hypertension and dyslipidemia: the respond trial. J
Clin Pharmacol 2007;47:1555–69.
Hobbs FD, Gensini G, Mancini GB, Manolis AJ, Bauer B,
Böhler S, et al. Can combining different risk interventions into a
single formulation contribute to improved cardiovascular disease
risk reduction? Rationale and design for an international, openlabel program to assess the effectiveness of a single pill
(amlodipine/atorvastatin) to attain recommended target levels for
blood pressure and lipids (The JEWEL Program). Int J Cardiol
;110:242–50.
Blank R, LaSalle J, Reeves R, Maroni J, Tarasenko L, Sun F.
Single-pill therapy in the treatment of concomitant hypertension
and dyslipidemia (the amlodipine/atorvastatin gemini study). J
Clin Hypertens (Greenwich) 2005;7:264–73.
Published
Issue
Section
License
Journal of Ayub Medical College, Abbottabad is an OPEN ACCESS JOURNAL which means that all content is FREELY available without charge to all users whether registered with the journal or not. The work published by J Ayub Med Coll Abbottabad is licensed and distributed under the creative commons License CC BY ND Attribution-NoDerivs. Material printed in this journal is OPEN to access, and are FREE for use in academic and research work with proper citation. J Ayub Med Coll Abbottabad accepts only original material for publication with the understanding that except for abstracts, no part of the data has been published or will be submitted for publication elsewhere before appearing in J Ayub Med Coll Abbottabad. The Editorial Board of J Ayub Med Coll Abbottabad makes every effort to ensure the accuracy and authenticity of material printed in J Ayub Med Coll Abbottabad. However, conclusions and statements expressed are views of the authors and do not reflect the opinion/policy of J Ayub Med Coll Abbottabad or the Editorial Board.
USERS are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.
AUTHORS retain the rights of free downloading/unlimited e-print of full text and sharing/disseminating the article without any restriction, by any means including twitter, scholarly collaboration networks such as ResearchGate, Academia.eu, and social media sites such as Twitter, LinkedIn, Google Scholar and any other professional or academic networking site.
